JP2025511081A - 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ - Google Patents

睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ Download PDF

Info

Publication number
JP2025511081A
JP2025511081A JP2024557755A JP2024557755A JP2025511081A JP 2025511081 A JP2025511081 A JP 2025511081A JP 2024557755 A JP2024557755 A JP 2024557755A JP 2024557755 A JP2024557755 A JP 2024557755A JP 2025511081 A JP2025511081 A JP 2025511081A
Authority
JP
Japan
Prior art keywords
dmt
meo
pharma
acceptable salt
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511081A5 (https=
JPWO2023186797A5 (https=
Inventor
タイス・ターヴィ
コナー・バーク
ニーシャ・ガフニー
Original Assignee
ジーエイチ・リサーチ・アイルランド・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーエイチ・リサーチ・アイルランド・リミテッド filed Critical ジーエイチ・リサーチ・アイルランド・リミテッド
Publication of JP2025511081A publication Critical patent/JP2025511081A/ja
Publication of JP2025511081A5 publication Critical patent/JP2025511081A5/ja
Publication of JPWO2023186797A5 publication Critical patent/JPWO2023186797A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024557755A 2022-03-27 2023-03-27 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ Pending JP2025511081A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000086 2022-03-27
EP22000086.3 2022-03-27
EP22000083.0 2022-03-27
EP22000083 2022-03-27
EP23153939.6 2023-01-30
EP23153939 2023-01-30
EP23153995 2023-01-30
EP23153995.8 2023-01-30
PCT/EP2023/057827 WO2023186797A1 (en) 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of sleep disturbance

Publications (3)

Publication Number Publication Date
JP2025511081A true JP2025511081A (ja) 2025-04-15
JP2025511081A5 JP2025511081A5 (https=) 2026-04-07
JPWO2023186797A5 JPWO2023186797A5 (https=) 2026-04-07

Family

ID=86007166

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置

Country Status (9)

Country Link
US (9) US20250213532A1 (https=)
EP (7) EP4499088A1 (https=)
JP (6) JP2025511081A (https=)
KR (6) KR20250005181A (https=)
CN (2) CN119053327A (https=)
AU (6) AU2023246774A1 (https=)
CA (6) CA3255505A1 (https=)
IL (6) IL315891A (https=)
WO (9) WO2023186829A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1625333A1 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
EP1884254B8 (de) 2006-08-01 2011-02-23 Stobi GmbH & Co. KG Ventilballon für Inhalatoren
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
MD3927338T2 (ro) * 2019-02-22 2025-03-31 Gh Res Ireland Limited Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale
EP4353314A3 (en) 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
KR20220009954A (ko) * 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
WO2021216489A1 (en) * 2020-04-20 2021-10-28 Lobe Sciences Ltd. Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury
WO2021250435A1 (en) * 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt

Also Published As

Publication number Publication date
KR20240167879A (ko) 2024-11-28
IL315898A (en) 2024-11-01
AU2023242291A1 (en) 2024-11-07
WO2023186823A1 (en) 2023-10-05
AU2023244452A1 (en) 2024-11-07
AU2023246774A1 (en) 2024-11-07
US20240108602A1 (en) 2024-04-04
IL315897A (en) 2024-11-01
WO2023186830A1 (en) 2023-10-05
US20250241892A1 (en) 2025-07-31
WO2023186797A1 (en) 2023-10-05
KR20250005183A (ko) 2025-01-09
EP4499088A1 (en) 2025-02-05
CA3255340A1 (en) 2023-10-05
US20250241895A1 (en) 2025-07-31
WO2023186826A1 (en) 2023-10-05
AU2023246543A1 (en) 2024-11-07
AU2023246679A1 (en) 2024-11-07
EP4499073A1 (en) 2025-02-05
US20250205256A1 (en) 2025-06-26
JP2025510369A (ja) 2025-04-14
CA3255505A1 (en) 2023-10-05
US20250241893A1 (en) 2025-07-31
US20250241891A1 (en) 2025-07-31
EP4499082A1 (en) 2025-02-05
WO2023186820A1 (en) 2023-10-05
IL315896A (en) 2024-11-01
WO2023186816A1 (en) 2023-10-05
US20240108601A1 (en) 2024-04-04
CA3255648A1 (en) 2023-10-05
EP4499075A1 (en) 2025-02-05
CN119095595A (zh) 2024-12-06
JP2025510912A (ja) 2025-04-15
CN119053327A (zh) 2024-11-29
WO2023186835A1 (en) 2023-10-05
EP4499076A1 (en) 2025-02-05
KR20250005176A (ko) 2025-01-09
KR20250005179A (ko) 2025-01-09
US20250205199A1 (en) 2025-06-26
AU2023246545A1 (en) 2024-11-07
KR20250005181A (ko) 2025-01-09
CA3255629A1 (en) 2023-10-05
WO2023186829A1 (en) 2023-10-05
KR20250005170A (ko) 2025-01-09
JP2025510916A (ja) 2025-04-15
JP2025512831A (ja) 2025-04-22
IL315902A (en) 2024-11-01
US20250213532A1 (en) 2025-07-03
WO2023186806A1 (en) 2023-10-05
EP4499083A1 (en) 2025-02-05
EP4499226A1 (en) 2025-02-05
CA3255348A1 (en) 2023-10-05
IL315899A (en) 2024-11-01
IL315891A (en) 2024-11-01
JP2025510368A (ja) 2025-04-14
CA3255343A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
JP2025511081A (ja) 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ
JP2025511084A (ja) 睡眠障害の処置に使用するための５－ｍｅｏ－ｄｍｔ
KR20250139377A (ko) 수유부의 정신 장애 치료에 사용하기 위한 5-메톡시-n,n-다이메틸트립타민
KR20250005172A (ko) 정신 장애의 치료
KR20250138805A (ko) 정신 장애의 치료

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260327